Human Serum Albumin-Oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer-Reference-Cited by-同舟云学术

Human Serum Albumin-Oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer

Published:2024-01 Issue: Volume:256 Page:128281
ISSN:0141-8130
Container-title:International Journal of Biological Macromolecules
language:en
Short-container-title:International Journal of Biological Macromolecules

Author:

Paul Milan,Ghosh Balaram,Biswas Swati

Publisher

Elsevier BV

Subject

Molecular Biology,General Medicine,Biochemistry,Structural Biology

Reference28 articles.

1. Triple-negative breast cancer molecular subtyping and treatment progress;Yin;Breast Cancer Res.,2020

2. Chemotherapeutic agents for the treatment of metastatic breast cancer: an update;Abotaleb;Biomed. Pharmacother.,2018

3. Nanocarriers for delivery of platinum anticancer drugs;Oberoi;Adv. Drug Deliv. Rev.,2013

4. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis;Poggio;Ann. Oncol.,2018

5. Basis for design and development of platinum (IV) anticancer complexes;Hall;J. Med. Chem.,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing breast cancer treatment: Harnessing the potential of albumin nanoparticles as targeted drug delivery vehicles;European Polymer Journal;2024-11

2. Tocopherol-human serum albumin nanoparticles enhance lapatinib delivery and overcome doxorubicin resistance in breast cancer;Nanomedicine;2024-07-02

3. Revisiting and Updating the Interaction between Human Serum Albumin and the Non-Steroidal Anti-Inflammatory Drugs Ketoprofen and Ketorolac;Molecules;2024-06-24

4. Rationalized landscape on protein-based cancer nanomedicine: Recent progress and challenges;International Journal of Pharmaceutics: X;2024-06

5. Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: in vitro cell-based anticancer studies;RSC Medicinal Chemistry;2024